Skip to content

Arrowhead Pharmaceuticals, Inc.

biopharmaceutical company

ARWR Nasdaq SEC CIK 879407

Follow Arrowhead Pharmaceuticals Weekly email: filings, results, news

News

5 stories filed under Arrowhead Pharmaceuticals, grouped into ongoing threads

For plozasiran

Thread · 3 stories

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia - Slideshow

Markets 22 d ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Discusses SHASTA-3 and SHASTA-4 12-Month Results for Plozasiran in Severe Hypertriglyceridemia Transcript

Markets 24 d ago

Could Arrowhead Pharmaceuticals (ARWR)’s Plozasiran Become the Catalyst for a Major Stock Re-rating?

Markets 27 d ago

More coverage

Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million

Markets 18 d ago

Arrowhead Pharmaceuticals, Inc. (ARWR) Presents at European Society of Cardiology (ESC) Congress 2026 - Slideshow

Policy 22 d ago

Next results

NOV3

Q2 2026 results

Tuesday · estimated from the filing cadence

Profile

Headquarters: PASADENA, CA, United States
Founded: 1989
Sector: Healthcare
Industry: Pharmaceutical Preparations
Website: arrowheadpharma.com

Peers

Where this page comes from

Profile · SEC EDGAR, Wikidata

Next results · estimated from the filing cadence (SEC EDGAR)

News · 5 stories clustered from the RSS aggregator